Tizanidine (Zanaflex; Novartis) has several pharmacokinetic and pharmacodynamic properties that predispose it to adverse drug interactions, including the following:
In a randomized controlled study of healthy subjects, pretreatment with fluvoxamine (100 mg/day for 4 days) resulted in a dramatic 33-fold increase in tizanidine area under the plasma concentration-time curve (AUC).1 The marked increases in tizanidine plasma concentrations were accompanied by pharmacodynamic changes, such as marked reduction in systolic blood pressure and increased sedation. These findings suggest a potentially dangerous drug interaction, and concurrent use of tizanidine and fluvoxamine is contraindicated. Fluvoxamine is a potent CYP1A2 inhibitor, which is probably the primary mechanism for this interaction.
Retrospective analysis of tizanidine pharmacokinetics in women taking oral contraceptives found that they had about a 50% lower clearance of tizanidine, compared with women not taking oral contraceptives. This finding is consistent with other evidence showing that estrogens are modest inhibitors of CYP1A2. In women taking oral contraceptives, tizanidine should be initiated with conservative doses and gradually increased based on response.
Other CYP1A2 Inhibitors
Since tizanidine appears to be very susceptible to interactions with inhibitors of CYP1A2, one should monitor for increased tizanidine response if any CYP1A2 inhibitor is used. Drugs known to inhibit CYP1A2 include atazanavir (Reyataz), ciprofloxacin (Cipro), enoxacin (Penetrex), mexiletine (Mexitil), tacrine (Cognex), and zileuton (Zyflo). Monitor particularly for excessive sedation and hypotension.
Sedation is a prominent side effect of tizanidine, and this is likely to be additive with any other CNS depressant. Tizanidine- induced sedation appears to be dose-related, so patients on larger tizanidine doses, and/or reduced CYP1A2 activity due to drugs or other reasons, would be at greater risk. Alcohol may increase tizanidine plasma concentrations somewhat and produce additive CNS depression, so patients should be warned to limit alcohol intake.
Tizanidine, like clonidine, is an alpha2-adrenoreceptor agonist and thus can produce hypotension when given alone or can enhance the hypotensive effects of other drugs. Two cases of acute hypotension have been reported (in a 10-year-old boy and a 48-year-old woman) when tizanidine was added to lisinopril therapy.2,3 Monitor blood pressure and patient response when tizanidine is initiated in patients receiving angiotensinconverting enzyme inhibitors or any other antihypertensive drugs. Since tizanidine is an alpha-adrenergic agonist, it generally should not be used with other alpha-adrenergic agonists such as clonidine, guanabenz, or guanfacine.
Drs. Horn and Hansten are both professors of pharmacy at the University of Washington School of Pharmacy. For an electronic version of this article, including references if any, visit www.hanstenandhorn.com.
For a list of references, send a stamped, self-addressed envelope to: References Department, Attn. A. Stahl, Pharmacy Times, 241 Forsgate Drive, Jamesburg, NJ 08831; or send an e-mail request to: email@example.com.
The Oncology Care Pharmacist in Health-System Pharmacy
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.
News from the year's biggest meetings
Clinical features with downloadable PDFs